For the Inventor, By the Inventor

Enter assignee name

Summit, NJ, United States of America

Novartis Corporation

USPTO Granted Patents = 166

% Expired Patents = 3.0

Trademarks = 19

Forward Citations = 3,180

Loading Chart...

Loading Chart...

340 inventors (with patents filed for the assignee):

Peter Maienfisch (6 out of 103 patents)

Norman Hardman (5 out of 8 patents)

Stephan Trah (4 out of 46 patents)

4. Hugo Ziegler (4 out of 39 patents)

5. Hans-Georg Brunner (4 out of 48 patents)

6. Laurenz Gsell (4 out of 64 patents)

7. Steven C Clark (4 out of 33 patents)

8. Elizabeth A Wang (4 out of 31 patents)

9. Nico Cerletti (4 out of 8 patents)

10. Cosima Nuninger (4 out of 9 patents)

11. Dino Sozzi (4 out of 9 patents)

12. Rene Zurfluh (4 out of 11 patents)

13. Georg Pissiotas (4 out of 91 patents)

14. John Edward Goggin (4 out of 5 patents)

15. Randal J Kaufman (4 out of 20 patents)

Core Competencies:

Osteoporosis Treatments

Monoclonal Antibodies

Ocular Sensors

Fungicidal Compositions

Insecticidal Matrix

Transgenic Drosophila

Biologically Active Proteins

Pharmaceutical Compositions

Herbicidal Compositions

Optical Sensors

Growth Factor Receptors

Antiviral Ethers

166 patents: Sort by Forward Citations

1. 8119105 - Aerosol container and a method for storage and administration of a pre-determined amount of a pharmaceutically active aerosol (2012-02-21),

2. 7465723 - Use of carboxamides for the treatment of tinnitus (2008-12-16),

3. 7253257 - Human metabotropic glutamate receptor subtype mGluR7b (2007-08-07),

4. 7057016 - Process for the production of biologically active protein (2006-06-06),

5. 6980842 - Ocular analyte sensor (2005-12-27),

6. 6900367 - Transgenic Drosophila melanogaster expressing a β42 in the eye (2005-05-31),

7. 6833241 - Mammary gland chemokine (2004-12-21),

8. 6596260 - Aerosol container and a method for storage and administration of a predetermined amount of a pharmaceutically active aerosol (2003-07-22),

9. 6515107 - Human metabotropic glutamate receptor 7 subtypes (2003-02-04),

10. 6358925 - Method and composition for the treatment of osteoporosis (2002-03-19),

11. 6300309 - Method and composition for the treatment of osteoporosis (2001-10-09),

12. 6294656 - Transforming growth factor &bgr; crystals (2001-09-25),

13. RE37344 - Ferrocenyl diphosphines as ligands for homogeneous catalysts (2001-08-28),

14. 6255288 - Certain methanebisphosphonic acid derivatives in fracture healing (2001-07-03),

15. 6228610 - Human metabotropic glutamate receptor subtypes (hmR4, hmR6, hmR7) and related DNA compounds (2001-05-08),

Novartis is a global healthcare company based in Switzerland that provides solutions to address the evolving needs of patients worldwide. With a diversified portfolio, Novartis operates in four key business segments: Innovative Medicines, Sandoz (generics and biosimilars), Alcon (eye care), and Advanced Accelerator Applications (radiopharmaceuticals). Committed to discovering innovative therapies and improving access to healthcare, Novartis aims to reimagine medicine to improve and extend people's lives.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Sep 22 2026

Novartis Corporation

166 Patents

#2 in Summit, NJ

#111 in New Jersey

#2,397 in US

#4,961 in the World

Summit, NJ, United States of America

Novartis Corporation

Forward Citations = 3,180

340 inventors:

Peter Maienfisch (6 out of 103 patents)

Norman Hardman (5 out of 8 patents)

Stephan Trah (4 out of 46 patents)

4. Hugo Ziegler (4 out of 39 patents)

5. Hans-Georg Brunner (4 out of 48 patents)

Please report any incorrect information to [email protected]

Loading…